Ukrain Therapy - International Research - Abstracts

254 International Scientific Medical References:

Austria, Belgium, Brazil, Germany, Greece, Egypt, India, Israel, Poland, Russia, Sweden, Switzerland, Thailand, USA.

13th International Congress of Chemotherapy, 28th August to 2nd September, 1983, Vienna, Austria.

 IV Mediterranean Congress of Chemotherapy, 19-25 October 1984, Rhodos, Greece.

V Mediterranean Congress of Chemotherapy. 26 October-1 November 1986 Cairo, Egyp,.

16th International Congress of Chemotherapy; 1, June 1989, Israel.

17th International Congress of Chemotherapy, 1991, Berlin, Germany.

VIII Mediterranean Congress of Chemotherapy, 24-29 May 1992, Athens, Greece.

18th International Congress of Chemotherapy,June 27-July 2, 1993, Stockholm, Sweden.

11th Future Trends in Chemotherapy, Interdisciplinary World Congress on Antimicrobial and Anticancer Drugs,
24-27 April 1994, Palexpo Geneva, Switzerland.

XVI International Cancer Congress 1994, 30 October - 5 November 1994, New Delhi, India

17th International Cancer Congress, August 24-28, 1998, Rio de Janeiro, Brazil.

Proceedings of the American Association for Cancer Research, March 1998, New Orleans, LA, USA.

Ukrain Therapy - Results - International Medical Research

Ukrain Therapy - Greater Celandine Plant Extract:

Cytotoxic Activity of Proteins Isolated from Extracts of Coryalia cava Tubers in Human Carvical Carcinoma HeLa Cells

Conclusions:

Presented studies confirm that biological activity of C. cava extracts may also be related to proteins contained in the extracts. For possible further applications, the biologically active plant proteins should be separated from alkaloids and other secondary metabolites, which in higher doses might be toxic [14].

The studies represent preliminary demonstration of the effect exerted by tuber proteins from a plant of pharmacological significance on cells of a tumour cell line. In the subsequent studies, an effort will be made to isolate the individual proteins and examine their effect on tumour cells individually and in combinations.

Discussion:

Plants that belong to family Papaveraceae, like Greater Celandine (Chelidonium majus L.) and Corydalis cava Schweig, & Koerte, are a rich source of various biologically active substances with strong pharma cological activity. The mechanism of this activity is still unknown, but very important compounds are the proteins contained in the plants. Our earlier studies showed that biological activity of Chelidonium majus milky sap may be related to its protein content .

* The protein fractions which contained two nucleases induced apoptosis in human cervical cancer HeLa cells [17].

Most probably, the present study represents the first investigations on the effect of purified PR proteins from tuber extracts of a pharmacologically active plant on cell lines. The cytotoxic effect of studied proteins toward HeLa cell line cells has been evident and dependent on increasing dose of the protein.

Results of protein identification in fractions from purification of C. cava tuber extracts using LC-ESI-MS/MS analysis have shown that proteins contained in bands of fractions 16-18 belong to plant pathogenesis - and defense-related proteins, indirectly or directly involved in plant defense reactions against stresses of various kind. Many of them belong to the PR protein family involved in plant defense against the pathogen attack. The family includes 17 protein classes of variable activities [24]. C. cava tubers are exposed to the attack of fungal, viral, bacterial and other pathogens during the entire vegetation season as well as during winter time [25].

* Accumulation of high number and variability of defense proteins in tubers together with several secondary metabolites, such as isoquinoline alkaloids, provides an effective and long-time protection against attack of pathogens.

*Moreover, defense-related proteins contained in C. cava tubers resemble 21 proteins identified earlier by our group in Chelidonium majus milky sap [15].

The studies represent preliminary demonstration of the effect exerted by tuber proteins from a plant of pharmacological significance on cells of a tumour cell line. The investigated protein fractions comprise a mixture of plant defense-related proteins. In subsequent studies, an effort
will be made to isolate the individual proteins and examine their effect on tumour cells individually and in combinations as well. Nevertheless, the synergistic action of all the compounds present in plant protein extracts is very important for their activity.

Many effective and extensively studied compounds of plant origin are, in fact, crude protein mixtures, such as phytotherapeutical drug bromelain, which is crude, aqueous extract from the stems and immature fruits of pineapples (Ananas comosus from the family Bromeliaceae), constituting a complex mixture of different thiol-endopeptidases and other components such as phosphatases, glucosidases, peroxidases, cellulases, glycoproteins, carbohydrates and several proteinase inhibitors [26].

Also, Viscum album L. extracts (VAE, European mistletoe) are composed of pharmacologically relevant compounds like: mistletoe lectins (ML I, II and III), viscotoxins and other low molecular proteins, VisalbCBA (Viscum album chitin-binding agglutinin), oligo- and polysaccharides, flavonoids, vesicles, triterpene acids, and others. Whole VAE as well as several of the compounds are cytotoxic and the mistletoe lectins have strong apoptosis-inducing effects [27].

Although the mechanism of presented activity of C. cava proteins is unknown, their defensive role for the plant could be very important. Many plant defense - related proteins belong to small (14-40 amino acids ), linear , cationic peptides.

*These peptides have membrane lytic properties and potent activity against a broad spectrum of microorganisms. They organize into ordered secondary structures (a-helix and b-sheet) in the membrane [28].

*Above a threshold concentration, peptides disturb the cell membrane and cause cell death due to membrane disintegration [29].

Ukrain - Cancer Therapy: - UKRAIN AND ITS POTENTIAL - http://www.ukrain.ua/

Ukrain has saved the lives of many cancer patients. This is proved by the fact that patients who were the first to use the preparation as monotherapy against metastasing tumours have lived for more than 20 years without relapse. For example, a patient with metastasing breast cancer on both sides who has been successful treated with Ukrain as monotherapy in 1983 (case breast cancer) and is still alive without recurrence.

Another example is a case of a colon cancer patient whose situation after surgery in 1988 has been evaluated as very serious and the prognosis was poor (case colon cancer) A leading Vienna oncologist evaluated this case as follows: ‘There is a status after surgery of an ulcerating colon adenocarcinoma with lymph node metastasing. Noteworthy is a large primary tumour, its ulceration and, moreover, the poor differentiation. All these factors indicate an unfavourable prognosis.’ Mrs. Jakob has been treated with Ukrain as monotherapy and is still alive without recurrence – 20 years after surgery.

Ukrain can cause the full regression of the main tumour and also of metastases. In the treatment of advanced tumours Ukrain can improve the quality of life and prolong survival. Many clinical studies have proved this, such as those of the work groups led by Prof. Beger in Germany and of Prof. Zemskov in Ukraine with pancreatic cancer (Gansauge 2002,Gansauge 2003, Gansauge 2007, Zemskov 2002), as well as groups led by Prof. Susak  and Prof. Bondar in Ukraine with colon cancer (Susak 1996, Bondar 1998). Neoadjuvant (before surgery) use of Ukrain can induce encapsulation of tumours as revealed the studies by the researchers of Grodno Medical University (Grodno, Belarus) in breast cancer (Uglyanica1996a, Uglyanica 1996b, Uglyanica 1996c, Uglyanica 1996d, Uglyanica 1996e, Uglyanica1996f, Uglyanica1998, incapsulation).

Ukrain is the first and only anticancer drug which accumulates in cancer cells minutes after administration. In contrast to chemotherapy the drug destroys only cancer cells by inducing apoptosis (programmed cell death) while leaving healthy cells undamaged.

At therapeutic dose the product has no appreciable adverse effects and does not damage healthy cells but only attacks cancer cells. Due to its very high therapeutic index of 1250 – in contrast to common cytostatics with a low TI of 1.4-1.8 – there is no danger of an overdose with Ukrain therapy (therapeutic index - ratio of toxic dose to the therapeutic dose). Ukrain also does not cause necroses with intramuscular administration.

This drug has been approved as standard anti-cancer medication in some countries of Europe and Asia (for example, Ukraine: first approval on October 18, 1998, #3641, re-approval on September 2, 2003, #3641; United Arab Emirates: registration no. 4987-6179-1; Georgia, 2008) as well as in Mexico (No. 036M2005 SSA). Ukrain has also been designated as an Orphan Drug for the treatment of pancreatic cancer in the USA (Designation Request #03-1693) and also in Australia (File 004/009839).

As noted above, through its antiangiogenic properties this medicine encapsulates tumours, thereby making them accessible to surgery. If possible, it is recommended to reduce the tumour burden within 10-14 days after the start of therapy.

The destruction of cancer cells with Ukrain is dose dependent. The higher the dose the more cancer cells are killed. Tumour degradation products such as amino acids, milk acid and others can release and induce transient local pain which can be treated with local sodium hydrogen carbonate compresses or oral intake of small quantities of sodium hydrogen carbonate solution (baking soda on knife top approx. 100-150 mg diluted in 250 ml water). This pain can be also treated with sodium bicarbonate solution as an infusion, see http://www.orthopaedie-dr-woelffle.de/neuraltherapie_neu_ulm.html ,http://www.neuraltherapy.com/, http://www.neuraltherapybook.com/.

At small doses, this preparation has an immune-modulating effect and significantly enhances malignotoxic activity of macrophages, lymphocytes and NK-cells against various cancer cells, i.e. it has properties related to cell mediated immunity. Due to these immune effects it improves the general condition of patients and is used to treat viral diseases. It is recommended to administer small doses of Ukrain immediately after surgery (during 3-5 days, 5 mg a day). It helps to regenerate the immune function, improve wound healing and rehabilitation and to prevent keloid scarring.

For successful treatment large doses of Ukrain should be alternated with small ones: large doses destroy tumours, small doses help to eliminate tumour degradation products. Therefore alternate doses are used in the course of Ukrain therapy, e.g. Monday 5 mg - Thursday 20 mg, or 5 – 30 mg, 5 – 40 mg, twice a week, with a two-day break after a small dose and a three-day break after a large one. There are reports on tumour regression after 10 day course of in-patient Ukrain therapy at a daily dose of 20 mg intravenously.

The mechanism of action of Ukrain has been tested on more than 100 cancer cell lines so far, including cisplatin-resistant lines, but also on normal cell lines. Ukrain has been proven to be effective against all cancer lines whereas normal lines were unaffected. In contrast to conventional cytostatics, which are toxic both against cancer and normal cells, Ukrain is toxic only against cancer cells and has been described as a malignotoxic agent.

Among other in vitro studies, Ukrain has been tested at the National Cancer Institute, Bethesda, Maryland, USA, on 60 cell lines representing eight important human malignant tumours: brain, ovarian, kidney, small cell and non-small cell lung carcinomas, colon cancer, leukaemia and melanoma. Ukrain was effective against all cell lines (NCI cell lines). In comparison with 5-fluorouracil (5-FU) and gemcitabine, two standard cytostatics in the treatment of abdominal carcinomas, Ukrain achieved better results having caused not only growth inhibition of cell lines but also reduction of cell mass. This advantage of Ukrain over 5-FU and gemcitabine was confirmed with clear clinical benefits in several randomised clinical studies (comparison 5-FU).

96 patients with colorectal carcinomas were included in a randomised study performed at the National Medical University, Kiev, Ukraine. 48 patients were treated with UKRAIN (15 of them with metastasing and 33 with non-metastasing colorectal tumours) and 48 patients were treated with 5-FU and radiotherapy. The survival rate after 21 months was 78.6% in the group treated with UKRAIN and 33.3% in the group treated with 5-FU and radiotherapy (Susak 1996).

48 patients with rectal carcinomas participated in a randomised study carried out at the Regional Cancer Center, Donetsk, Ukraine. 24 patients received high-dosage radiotherapy and 5-FU before surgery, and another 24 patients received one series of UKRAIN therapy before surgery (10 mg on alternate days, up to a total dose of 60 mg) and one series after surgery (up to a total dose of 40 mg). During the following 14 months, 25% of patients who had received 5-FU and radiotherapy had relapses but only 8.3% of patients who had received UKRAIN. During the following two years, 33.3% of patients who had received 5-FU and radiotherapy had relapses but only 16.7% of the patients who had been treated with UKRAIN (Bondar 1998).

90 patients with histologically verified advanced pancreatic cancer were treated in a controlled randomised study by Prof. Beger et al. at the University of Ulm, Germany. Patients in group A received gemcitabine 1000 mg/m2, those in group B received 20 mg UKRAIN, and those in group C received 1000 mg/m2 gemcitabine followed by 20 mg UKRAIN per week. Survival rates after six months were 26% in group A, 65% in group B and 74% in group C. The results showed that in inoperable advanced pancreatic cancer, survival rates were doubled using UKRAIN in combination with gemcitabine (Gansauge 2002).

Patients were further observed after the conclusion of the study and it was noted that UKRAIN was well tolerated and could be administered without problem to all patients. UKRAIN brought about a significant increase in survival time in comparison to therapy with gemcitabine alone. Combination therapy with gemcitabine and UKRAIN showed no advantage over monotherapy with UKRAIN. The longest survival in the gemcitabine group was 19 months, 21 months in the gemcitabine+Ukrain group, and in the Ukrain group a patient was still alive after 28 months. The authors concluded: ‘As a result of this study we highly recommend the treatment of patients suffering from advanced pancreatic cancer with Ukrain’ (Gansauge 2003).

The recent clinical study by the same group (University of Ulm, Germany) provided additional data on the benefit of a combined adjuvant treatment with Ukrain and gemcitabine. The relapse-free survival time was 21.7 months, and median survival 33.8 months which is clearly better than results reported in the literature earlier, for example 20.4 months in the study by Kurosaki et al, 2004. The actuarial survival rates were 86.7% after one year, 76.6% after two years, 46.7% after three years and 23.3% after five years (these patients are still alive). Again, this publication supports the efficacy (and safety) of the use of Ukrain as it demonstrates a considerable prolongation of survival compared to what is known from other clinical studies (Gansauge 2007).

The selective effect of Ukrain as well as its mechanism of action has been proven in many studies by researchers from various countries.

In the study by Hohenwarter et al. the inhibitory effect of Ukrain on malignant and normal cells was compared. To obtain a 50% growth inhibition, a tenfold concentration had to be used with normal endothelial cells compared to a human osteosarcoma cell line. Laser scanning microscopy showed a high uptake of Ukrain in malignant cells while the content in normal cells under the same experimental conditions was substantially lower (Hohenwarter et al, 1992; used cell lines: human osteosarcoma and melanoma cell lines; human endothelial cells from umbilical vein).

At the 89th annual meeting of the American Association for Cancer Research in New Orleans, March 28 – April 1, 1998 A. Panzer and J.C. Seegers (University of Pretoria, South Africa) presented their work on the selective effect of Ukrain on various cancer cell lines. The authors concluded “that Ukrain is selectively toxic to malignant cells by causing a metaphase block which is characterised by abnormal chromosomal distribution, and results in the formation of micronuclei and in apoptosis” (Panzer and Seegers, 1998; used cell lines: human cervical carcinoma HeLa and human foreskin fibroblasts Hs27, squamous oesophageal cancer WHCO5; transformed human embryonic kidney Graham 293, and transformed African green monkey kidney Vero).

In 2000 the group from South Africa published another article in which the selective mode of action of Ukrain was denied (Panzer et al, 2000). The authors did not explain the contradiction in the results of their two studies. The Ukrain opponents called the authors' group ‘independent’; however, the results of the study which denied the selective effect of Ukrain could not be reproduced by any other research group.

In the tests on epidermoid carcinoma cells as well as prostate cancer cell lines, Roublevskaya et al. from Rochester University, USA revealed Ukrain to induce the G2M accumulation of cancer cells but not of normal cells. The researchers also observed an upregulation of CDK inhibitor p27 in cancer cell lines (Roublevskaya et al., 2000a, 2000b; used cell lines: epidermoid carcinoma ME180 and A431, prostate cancer LNCaP; normal human keratinocytes HaCaT).

This malignocytolytic effect of Ukrain in prostate cancer was confirmed in clinic. 74 patients with prostatic carcinoma were involved in a controlled study at the Villa Medica Clinic (Edenkoben, Germany). These patients had already been treated according to all conventional therapy protocols, and due to relapse and/or progression of the disease had no further conventional options available. They were treated with UKRAIN, and partially at the same time with local hyperthermia, and the following results were obtained: complete remission (full tumor disappearence) in 73% of patients and partial remission (partial tumor disappearence) in 22%, with only 5% of patients showing no effect on the progress of the disease.

Cordes et al. from Eberhard-Karls-University Tubingen, Germany, investigated the effects of Ukrain on cell survival, alteration of the cell cycle and induction of apoptosis without and in combination with ionising radiation (IR). Ukrain modulated radiation toxicity of human cancer cell lines and protected normal cells from radiation. The combination of Ukrain plus IR gave enhanced toxicity in CCL-221 and U-138MG cells but not in MDA-MB-231 and PA-TU-8902 cells. A radioprotective effect was found in normal human skin and lung fibroblasts (Cordes et al, 2002; used human cell lines: breast carcinoma MDA-MB-231, pancreas carcinoma PA-TU-8902, colorectal cancer CCL-221, glioblastoma U-138MG; skin fibroblasts HSF1, HSF2, and lung fibroblasts CCD32-LU).

The mechanism of action of NSC 631570 on pancreas cancer was studied on human cell lines AsPC1, BxPC3, Capan1, MiaPaCa2 and Panc1. After pre-incubation, semiconfluent cultures were incubated with FCS-free medium for 24 hours and covered with FCS-supplemented medium and different concentrations of thiophosphoric acid, chelidonine and NSC-631570. Cells for staining procedures were cultured under similar conditions on chamber slides. For cell cycle analyses, proliferation assays and mitose phase analyses, cells were harvested 24 and 48 hours after incubation with 20 ng/ml, 60 ng/ml, 0.2 µg/ml, 0.6 µg/ml, 2 µg/ml, 6 µg/ml and 20 µg/ml chelidonine or 1 µg/ml, 5 µg/ml, 10 µg/ml and 20 µg/ml NSC-631570 or 0.144 µg/ml, 1.44 µg/ml and 2.88 µg/ml thiophosphoric acid or mixtures of chelidonine and thiophosphoric acid. Serial experiments at 4-hour intervals with AsPC1 and immunfluorescence stainings were performed using 0.6 µg/ml chelidonine or 10 µg/ml NSC-631570.

Cell cycle analysis, proliferation assays, DNA laddering, Western blot analysis, and in vitro polymerisation of tubulin were then performed. Authors observed that NSC-631570 induces G2/M-arrest in pancreatic cancer cells. Furthermore, they discovered that it arrests cells in G2/M in a dose- and time-dependent fashion. Serial experiments also revealed that the effects on cell cycle phases caused by 10 µg/ml NSC-631570 are already irreversible after an incubation period of 8 hours. In-vitropolymerisation of monomeric tubulin revealed that NSC-631570 stabilizes tubulin monomers and as a result inhibits microtubule network assembly (Ramadani et al, 2000).

In an experimental study assessing cell proliferation by BrdU-incorporation into pancreatic cancer cell lines (AsPC1, BxPC3, MiaPaCa2, Jurkat and THP-1) and cell cycle analysis by Giemsa staining, NSC 631570 (10 mg/ml) was shown to induce a high accumulation of treated cells in the G2/M phase after 24 hours incubation. The rate of apoptosis in similarly treated peripheral mononuclear cells did not show any differences between treated and untreated cells; further, mitogen-stimulated lymphocytes showed an increased blastogenic response (Gansauge et al, 2001).

An Italian research group, Gagliano et al. from the University of Milan, used RT-PCR, Western blot and SDS-zymography to investigate the effects of Ukrain on the expression of genes and proteins involved in the extracellular matrix remodelling associated with tumour invasion in human cultured glioblastoma cells. There was a significant, dose-related decrease in glioblastoma cell proliferation and a tendency to the downregulation of SPARC (secreted protein acidic and rich in cysteine) after treatment with Ukrain, suggesting ‘the drug may be a useful therapeutic tool for brain tumours’ (Gagliano et al, 2006; used cell lines: human glioblastoma MI lines T60, T63, and GBM).

Researchers at the Instituto Nacional de Cancerologia, Mexico City, Mexico ‘revealed that Ukrain induced apoptosis in a panel of cancer cell lines by activating the intrinsic cell death pathway. Interestingly, nontransformed fibroblasts (hTERT) cell line was insensitive to the drug.’ (Mendoza et al, 2006; used cell lines: cervical cancer HeLa, HeKB, HeKS32, HeBcl3, HeNFR and HeIKK, human colon cancer SW480, human renal carcinoma HEK293, human osteosarcoma MG-63, and immortalised human fibroblasts hTERT).

The Italian research group, (Gagliano et al. from the University of Milan) has extended their research in glioblastoma. In the 2007 published study authors reported that after treatment with Ukrain, glial fibrillar acidic protein (GFAP) fluorescence increased and a higher number of glioblastoma cells displayed GFAP organized into a filamentous state. Western blot analysis confirmed that Ukrain tended to upregulate this protein. Connexin 43 was not modulated by Ukrain. Ukrain induced apoptotic rate was up to 28.9%, likely mediated by cytochrome c release in the cytoplasm (Gagliano et al, 2007).

This selective effect of Ukrain on cancer cells has been proven not only with autofluorescence under UV-light (Nowicky et al, 1988) and pharmacokinetics (Doroshenko et al, 2000) but also in many in vitro experiments and several clinical studies. UKRAIN tests on healthy probands showed no side effects. At therapeutic dose Ukrain has minimal adverse effects. These adverse effects can occur in cancer patients during therapy and may be explained by the action of tumor degradation products. These effects disappear when the tumor is in complete remission.

The biggest wish of all oncologists has been to develop an agent that is only toxic against cancer cells. For a long time this aim was considered impossible. The drug Ukrain makes the dream a reality and has taken the first big step towards the solution of this problem.

The wide spectrum of cancer cell lines where Ukrain is effective explains its use in the treatment of various malignant tumours. In Ukraine, Georgia and Mexico Ukrain is officially registered for the treatment of various types of cancer.

Thanks to the unique properties of the preparation the inventor of this medication was nominated for the Nobel Prize in 2005 and for the Alternative Nobel Prize in 2007.

Ukrain Therapy - Cancer - Bladder Cancer

28 patients with carcinoma of the bladder were divided into three groups for a prospective controlled clinical trial using either one, two or three cycles of UKRAIN therapy, with a two-week interval between cycles. Each cycle consisted of 10 mg/day intravenously, over 10 days. Tumors were assessed by cystoscopy and ultrasound before and two weeks after the end of treatment.

Response to therapy (complete or partial remission) was observed in four from nine patients receiving one cycle of UKRAIN, in five from ten receiving two, and in eight from nine receiving three cycles. In no case was any growth of the tumour observed. No adverse events were reported. The authors concluded that better results are obtained with longer treatment. (Uglyanica et al, 1998).

Ukrain Therapy - Cancer - Brain Tumors

The effect of Ukrain on the expression of genes and proteins involved malignant growth in the cultured human glioblastoma cells (brain tumor) was investigated by the research group of Milano University, Italy.

Three human glioblastoma cell lines T60, T63 and GBM were treated with three concentrations of Ukrain (0.1, 1 and 10 µmol/l). Untreated cultures served as controls. The high dose (10 µmol/l) significantly reduced cell proliferation after 48 h and 72 h. There was also a tendency to downregulation of MMP-2 and SPARC 48 and 72 h after incubation with Ukrain. Ukrain influences some major aspects of progression in human glioblastoma cells, such as cell proliferation and the expression of a pivotal protein in the mechanisms, leading to tumor cell invasion and survival. Thus, Ukrain may have some potential for the therapy of brain tumors, and could well also help extend our understanding of the mechanisms of this anti-tumor and chemopreventive potential (Gagliano et al, 2006).

Successful use of Ukrain in the patients with brain tumors are illustrated in the following case reports.

In a 25 year old male patient a left sided, frontal chestnut-sized tumour was diagnosed and extirpated sub-totally. Histological examination demonstrated an anaplastic grade III astrocytoma. Treatment with Ukrain was started 7 weeks after the operation (cycles of 2x20 mg iv/w, for 5 weeks, with 2w treatment-free intervals between cycles). The tumour progression slowed down and the patient was still in good condition two years later (Steinacker et al, 1996).

In a 33 months- old female patient an astrocytoma of the optic nerve was diagnosed and extirpated sub-totally. The tumor progressed over the next 52 months. The patient received neither chemotherapy nor radiation. Treatment with Ukrain was started 52 months after the first operation (2 mg to 15 mg i.v., up to a total dose of 723 mg Ukrain over 13 months). Disease progression was slowed down and an almost stable condition was achieved (Steinacker et al, 1996a).

Another case of a 13-years old girl with a 2.2 cm large tumour in the region of the septum pellucidum, extending into interventricular foramina and obstructing the cerebrospinal fluid pathway. Following two previous interventions to evacuate the epidural hamartoma to drain the left ventricle due to hydrocephalus, the patient underwent partial tumour extraction. On histological examination a giant cell astrocytoma was found. Three months later treatment with Ukrain was started (2x5 mg i.v./week, 6 months) and remission was achieved. Tumour nodules seen in the CT diminished in size, three of five non-operated tumour nodules completely disappeared, as well as a CSF pathway obstruction and the neurological condition improved (Nowicky et al, 2003).

Ukrain Therapy - Cancer - Breast Cancer

The effect of Ukrain on breast cancer has been studied in vitro on the cell line MDA-MB-231 (Cordes et al, 2002) and in vivo as well.  

In a study from Miami University, USA, BALB/C mice (15 animals) received subcutaneous injection of transplantable rapid growth mammary adenocarcinoma (D1 DMBA-3). On day 14, in the group receiving intravenous treatment with Ukrain, tumour growth had slowed down significantly (p<0.05). These data indicate that in vivo effects of Ukrain against the development of mammary tumours may be due, at least in part, to its ability to restore macrophage cytolytic function (Sotomayor et al., 1992).

75 patients with breast cancer (clinical stages I, II, III, T1-3N0-2M0, ages up to 70 years) were the subject of a controlled clinical study conducted at the University Grodno (Belarus). They were divided into three groups, with 25 patients in each. Those in the first group received UKRAIN prior to their operation in the dosage of 5 mg every second day, to a total dosage of 50 mg, while those in the second group similarly received 10 mg of UKRAIN every second day to a total dosage of 100 mg. Those in the third (control) group were not treated with UKRAIN before their operation.

After treatment with UKRAIN, hardening of the tumor, and proliferation of connective tissues were observed. The ratio of T4/T8 lymphocytes increased by 30%. Eight to ten weeks after surgery, levels of ESR (a blood test to monitor inflammation in the body, which routinely increases after an operation) were found to be little more than half as high in the groups that had received UKRAIN, compared with the control group. This indicated faster post-operational healing and improvement in general condition of patients from the groups receiving UKRAIN.

The patients who were treated with a higher dosage of UKRAIN reported slight pain in the cancer area, and a slight increase in fever. However, faster tumour remission was observed in these patients. The tumours appeared harder and slightly enlarged after UKRAIN therapy, and were easier to detect by ultrasound or radiological examination. Metastatic lymph nodes were also hardened and sclerotic (fibrous). Through this hardening process under the influence of UKRAIN, tumours and metastatic lymph nodes were clearly demarcated from healthy tissue and therefore easier to remove.

Complications such as prolonged lymphorrhoea (leakage of lymph), skin necrosis (death of skin tissue), suppuration of the wound, and pneumonia, all occurred in patients from the two UKRAIN groups at only half the rate than they appeared in patients from the control group.

Based on the results of this study the scientists from the Medical University Grodno recommended the use of UKRAIN, at the higher dosage, before all breast cancer operations.

Ukrain Therapy - Cancer - Colerectal Cancer

In the in vitro screening program of National Cancer Institute in Bethesda, USA, the effect of Ukrain (NSC 631570) on colon cancer cell lines among other was examined.

UKRAIN showed a pronounced growth-inhibiting effect in colorectal cancer cell lines, which in higher concentrations developed into a cytolytic effect leading to a reduction in cell biomass. 5-Fluorouracil, the standard chemotherapeutic agent to treat colon cancer actually, (5-FU, ascribed code: NSC 19893) was examined under identical conditions and the dose-response curves for 5-FU showed inhibition only in 8 human colon cancer cell lines in a 10-3.5 molar sample concentration, which is 10 times higher than the concentration of Ukrain.

No lethal effects could be achieved with 5-FU on human colon cancer cells with this method; nevertheless the NCI judged that the anticancer activity of this compound was outstanding. The dose-effect plots of 5-fluorouracil were much flatter than those for Ukrain, and only in single cases and extremely high doses, displayed complete growth inhibition but not malignocytolytic effect as in the case of Ukrain. In this study Ukrain confirmed its malignocytolytic effect.

These promising results found confirmation in two randomised clinical trials. 96 patients with colorectal carcinomas were included in a randomised study conducted by Prof. Susak and Prof. Zemskov (National Medical University Kiev, Ukraine). 48 patients were treated with UKRAIN (15 of them with metastasising and 33 with non-metastasising colorectal tumours) and 48 patients were treated with the chemotherapeutic drug 5-FU and radiotherapy. The survival rate after 21 months was 78% in the group treated with UKRAIN and 33% in the group treated with 5-FU and radiotherapy.

In another trial, a total of 48 patients suffering from rectum cancer were included in this randomized study conducted at the Proctology Department of the Donetsk Regional Anti-Cancer Center. The 24 patients in group I were treated with Ukrain as monotherapy. 10 mg each second day before operation (up to a cumulative dose of 60 mg) and a total of 40 mg after surgical intervention. Repeated Ukrain courses (100 mg per course) were also given 6 months after surgical operation. Patients in group II (24 patients) received an intensive course of high fractional X-ray therapy (cumulative dose up to 25 Gr) with direct protracted endolymphatic chemotherapy with 5- fluorouracil (5-FU) instilled in 600 mg/m each day before operation, up to a cumulative dose of 5 g.

In each case preoperative treatment was followed by routine surgical operation. 12-years survival in patients of the I group was as much as 75% (6 patients died), in patients of the II group - 45,8% (13 patients died). Comparative investigation of objective and subjective signs, analysis of results of instrument and X- ray data, as well as dynamic study of the histological structure of rectal tumors, indicate that Ukrain exerts a more potent malignotoxic and immunomodulating action than other types of anticancer treatment.

Ukrain Therapy - Cancer - Lung Cancer

In the tests of NCI Ukrain has been proven to be effective against both most important variants of lung cancer – non-small cell lung cancer and small lung cancer. Its efficacy was later confirmed in a clinical study (Staniszewski et al, 1992) as well as in many clinical observations.

Ukrain Therapy - Cancer - Melanoma Cancer

In several tests the effect of Ukrain on melanoma cell lines was evaluated. High uptake of Ukrain in melanoma cells in vitro was revealed in the study Hohenwarter et al, 1992.

Antimetastatic effect of Ukrain in mice with melanoma B-16 was studied. Ukrain was shown to inhibit the growth of the primary tumour and its metastases (Zemskov et al., 1996).

These results were confirmed in clinic. A long lasting benefit (12 years of no recurrence) was observed in a patient with a malignant nodular stage III melanoma, echo-reflexing zones in the ultrasound-scan of the liver and positive melanin excretion indicating diffuse metastasing at the time of diagnosis and who was subsequently treated with Ukrain (10 mg i.v., twice weekly) for 21 months (Hamler et al, 1996).

Ukrain Therapy - Cancer - Oesophageal Cancer

The efficacy of Ukrain in oesophageal cancer has been proven in vitro and then in a case report.

A patient with poorly differentiated squamous cell oesophageal carcinoma, inoperable according to clinical and X-ray contrast examinations, was treated first with 40 courses of radiation (maximal dose), followed by three courses of chemotherapy (cisplatin, methotrexate, bleomycin) without response. Nine months after the diagnose had been established, treatment with Ukrain was started (20 mg every 2nd day for 2 weeks, followed by 10 mg every 2nd day up to 230 mg). The patient was free of tumor recurrence up to the last observation 42 months later (Vyas et al, 1996).

It is well-known that often agents with promising preclinical results failed in clinical trials. This was not the case for UKRAIN where clinical use always confirmed good preclinical results. Moreover, Ukrain is effective also in cancer types where no in vitro study has been performed so far.

Ukrain Therapy - Cancer - Pancreatic Cancer

The recent clinical study by Gansauge et al, 2007 provided additional data on the benefit of a combined, adjuvant treatment with Ukrain and gemcitabine. The relapse-free survival time was 21.7 months, and median survival 33.8 months compared to 20.4 months (Kurosaki et al, 2004), what is clearly better compared to the literature. The actuarial survival rates were 86.7% after one year, 76.6% after two years, 46.7% after three years and 23.3% after five years (these patients are still alive).

Again, this publication supports the efficacy (and safety) of the use of Ukrain as it demonstrates a considerable prolongation of survival compared to what is known from literature.

Patients in the study by Gansauge et al, 2002 on palliative treatment of pancreas cancer were further observed after the conclusion of the study and it was noted that UKRAIN was well tolerated and could be administered without complications to all patients. UKRAIN brought about a significant increase in survival time in comparison to therapy with Gemcitabine alone. Combination therapy with Gemcitabine and UKRAIN showed no advantage over monotherapy with UKRAIN. In the gemcitabine group the longest survival was 19 months, in the combination group 26 months, whereas in the Ukrain alone group three patients lived longer than 28 months and were still alive at the time of publication.

As world leading expert in pancreas carcinoma treatment Prof. H.G. Beger of the Ulm University, Germany, author of 21 books and more than 600 scientific publications was unsatisfied with the results of the therapy in this very aggressive cancer, he was looking for new therapy modalities. Prof. Beger paid attention on the medicine Ukrain and started in vitro tests. In the tests with pancreas cancer cell lines Jurkat, MiaPaCa2, AsPC1, BxPC3 und THP-1 the researchers of Prof. Beger’s group revealed Ukrain has a strong malignocytolytic effects on these cell lines. The mitotic analysis revealed mitotic arrest of cancer cells in the prophase and/or metaphase. This was a very important study to clarify the exact mechanism of action of Ukrain.

After the researchers from the University of Ulm have proved in vitro the efficacy of Ukrain against pancreas cancer cell lines and revealed the mechanism of action of Ukrain, Prof. Beger reviewed preclinical toxicity data, ascertained the safety of the drug and performed a pilot clinical trial

In this study 90 patients with histologically verified inoperable pancreatic cancer were treated in a controlled, randomised study at the University of Ulm (Germany). Patients in Group A received the standard chemotherapeutic drug Gemcitabine 1000 mg/m2 body area, those in Group B received 20 mg UKRAIN, and those in Group C received 1000 mg/m2 Gemcitabine followed by 20 mg UKRAIN per week. Survival rates after 6 months were 26% in the gemcitabine group, 65% in Ukrain Group B and 74% in the combination Group. The results showed that in inoperable advanced pancreatic cancer, survival rates were doubled using UKRAIN in combination with gemcitabine.

As a consequence of the results of this study the doctors from the University of Ulm recommend UKRAIN monotherapy in the palliative treatment of advanced pancreatic cancer – one of the most aggressive and resistant to treatment.

In another study by Prof. Zemskov et al. (National Medical University Kiev, Ukraine) 42 patients with pathologically verified pancreatic cancer were randomly enrolled in either of two groups: one group received vitamin C plus UKRAIN, the control group vitamin C plus best supportive care. The UKRAIN therapy dose was 10 mg intravenously every second day, to a total of 100 mg per patient. The survival rate after one year was 76% in the group treated with UKRAIN as opposed to 9.5% in the control group. The survival rate after two years was 48% in the UKRAIN-treated group with the longest survival of 70 months, and 5% in the control group. This study confirmed that best results can be achieved with Ukrain monotherapy.

A total of 28 patients with pancreatic adenocarcinoma were treated with Ukrain between August 1997 and December 2003 in the clinic Villa Medica, Germany. All the patients presented with advanced and/or metastatic disease that made curable radical surgery impossible. Twenty-one patients had previously been treated with 5-fluorouracil or gemcitabine, but due to disease progression this therapy was discontinued. Seven patients rejected conventional chemotherapy.

Ukrain was administered at a dose of 20 mg three times a week for the first three months and then at a dose of 20 mg once a week for 4 months (total dose: 320 mg). Ukrain was generally well tolerated. Partial remission was achieved in 24 cases (85.7%) while four patients (14.3%) did not respond to treatment. Twenty-four patients described their quality of life during Ukrain treatment as “good”, and all the patients noted improvement in their general condition after treatment with Ukrain. The mean survival of the patients treated with Ukrain was 26.1 months.

These results demonstrate efficacy of Ukrain against one of the most aggressive and resistant cancer. This action observed both in vitro and in clinic. This is the reason for wide efficacy of this drug in various tumors.

Ukrain Therapy - Cancer - Prostate Cancer - 01

The effect of Ukrain on the prostate cancer has been studied by several research groups in vitro. The group from Rochester University, USA used the cell line LNCaP.

Ukrain induced morphological changes with cells becoming elongated and spindle shaped. Flow cytometry revealed a dose-dependent increase in the number of apoptotic cells. At 3.5 M, Ukrain treatment resulted 73% of cells G2/M-phase compared to 10% of control cells. Although the number of cells in G2/M-phase decreased with increasing dose, the number of apoptotic cells increased. UKRAIN was found to up-regulate the expression of the cyclin-dependent kinase inhibitor, p27 (Roublevskaia et al., 2000).

This malignocytolytic effect was confirmed in clinic. 74 patients with prostatic carcinoma were involved in a controlled study at the Villa Medica Clinic (Edenkoben, Germany). These patients had already been treated according to all conventional therapy protocols, and due to relapse and/or progression of the disease had no further conventional options available. They were treated with UKRAIN, and partially at the same time with local hyperthermia, and the following results were obtained: complete remission (full tumor disappearence) in 73% of patients and partial remission (partial tumor disappearence) in 22%, with only 5% of patients showing no effect on the progress of the disease. Many physicians also observed tumor remissions after the out-patient treatment of prostate cancer.

Ukrain Therapy - Cancer - Prostate Cancer - 02

RESULTS OF UKRAIN MONOTHERAPY OF PROSTATE CANCER

UGLYANITSA K.M.,1 NECHIPORENKO N.A.,1 NEFYODOV L.I.,2 DOROSHENKO Y.M., BRZOSKO W.,3 NOWICKY W.4

1) Oncology Department, Higher Medical School, Grodno, Belarus.
2) Laboratory of Analytical Biochemistry, Institute of Biochemistry, National Academy of Sciences, Grodno, Belarus.
3) R. Brzosko Memorial Center of Natural Medicine, Warsaw, Poland.
4) Ukrainian Anti-Cancer Institute, Vienna, Austria.

Address for correspondence: K.N. Uglyanitsa, Oncology Department, Higher Medical School, ul Gorkogo 80, 230015 Grodno, Belarus

Summary: This study included 15 patients with newly diagnosed prostate cancer with an average age of 71 years (62-85 years). The patients received Ukrain at a total dose of 100 mg (10 mg intravenously every second day, 10 injections altogether).

*After two to three injections of Ukrain, all the patients noted considerable subjective improvements in their state.

*Ukrain increased the amount of total T-lymphocytes, including "active" T-lymphocytes, decreased the content of T-suppressors and increased that of T helpers, correspondingly raising the T-helper/T-suppressor ratio.

*Our results undoubtedly indicate the efficacy of Ukrain in the treatment of prostate cancer.

Ukrain Therapy - Cancer - Stomach Cancer

There are also case reports with successful treatment of stomach cancer with Ukrain.

Ukrain Therapy - Cancer - Uterine Cancer

Advanced Uterine Cancer with Neoplasic Infiltrative Lesions

The result obtained in 4 months time as observed on the hospital reports (and RMI) before and after is quite impressive while it eliminates the need of radiation therapy which has a controversial role in uterine cancer and may even increase metastasis expansion as observed in many cases. First we have clearly demonstrated the synergistic effect of our combination therapy.

L.C.E. may inhibit making of new vascularisation but also induce apoptosis of blood vessels reaching the tumor. The antioxidant compound Anoxe decrease oxidative stress, inhibit COX2 activity that in turn decrease angiogenic factors. COX2 overexpression is linked to chemotherapy and radiation treatment resistance in patients with most tumors. With much less resistance and by conjointly attacking the tumor via cytotoxicity of anticancer drugs high dose of antioxidants and less vascularizarion the tumor start to shrinke and therefore can be more vulnerable to immune cells activate by the immunostimulant Biobran.

The result is an increase in the number of cancer cells destroy jointly by chemotherapy and the immune system. Simultaneously we demonstrate that antioxidants do not interfere with the effectiveness of chemotherapy but on the contrary increase the cytotoxicity. We also demonstrate that LCE has strong angiogenic inhibitory property by targeting the angiogenic cascade from several direction and to increase chemotherapy effectiveness.

Medical doctors are confuse and mistaken when they say that “shark cartilage” is not beneficial but also decrease survival in cancer patient. We have a case of pancreas cancer with metastasic condition and awaiting for chemo/radiation.

In meanwhile in 2 weeks time taking only LCE – CA 19.9 decrease from 132 U/ml to 101 U/ml.

Ukrain is a natural chemotherapeutic agent made from an extract of the chelidonium plant majus that demonstrate strong cytostatic activity against cancer cells. Ukraine has shown an immune modulating effect with smaller doses (5 mg) and a malignocytolitic effect with larger doses (20 mg).

We have use Ukraine with success for now a member of years and observed better result on large tumor when include in a combination therapy like in this particular case but indeed Ukraine is a pillar in our cancer treatment.

Therefore in this particular cancer case we simply shown that alternative medicine is on the contrary of doctors claim much efficient and simultaneously with chemotherapy increase remission rate and may indeed achieve clinical result totally impossible with chemotherapy alone.

Ukrain Therapy - Cancer - Conclusion

To date UKRAIN has been tested on more than 100 cancer cell lines and has proved its malignotoxic effect against all of them, including pancreatic cancer cell lines and cell lines which were resistant to the chemotherapy drug cisplatin, as well human tumour xenografts. The wide spectrum of efficacy of Ukrain was confirmed in the following pilot study.

363 cancer patients with 47 different types of tumours were treated with UKRAIN between September 1997 and January 2003 at the Villa Medica Clinic (Edenkoben, Germany) under the medical direction of Dr. Aschhoff. These patients had already exhausted conventional means of therapy without success, and because of relapse and/or continued progression of the disease, UKRAIN therapy was undertaken. Nevertheless, the following rates of recovery (full remission) were achieved: breast cancer 31%, colorectal cancer 16.7%, lung adenocarcinoma 7.7%, small-cell lung carcinoma 21%, astrocytoma (brain tumor) 66.6%, neuroblastoma 60%, seminoma (testicular cancer) 75%, bladder carcinoma 50% (Aschhoff, 2003).

Toxicity studies, preclinical and clinical studies revealed Ukrain to be non-toxic and its use is safe. Because it triggers apoptosis in cancer cells Ukrain is only toxic against cancer cells while, in contrast to common chemotherapy, it leaves healthy cells undamaged. Through its antiangiogenic properties this medicine encapsulates tumours, thereby making them accessible to surgical intervention. In addition, Ukrain has an immune-modulating effect, whereby it improves the general condition of patients and does not only prolong their lives but in many cases also effects a recovery.

All this was the reason for physicians to use this medicine in the treatment of cancer patients also in many countries where an application for marketing authorisation for Ukrain has not been applied yet.

We allow us to publish here the references of physicians from these countries.

Acknowledgment

All studies performed with UKRAIN so far were not financed by a pharmaceutical company but were investigator initiated studies. Researchers which performed these studies worked for the enrichment of world science and to enable better therapy of cancer patients. Having presented their research work on international congresses they awoke broad interest of the international scientific community.

They enabled broad clinical use of Ukrain and made a valuable contribution to the improving and saving many lives. We express our deep thanks to all these scientists. You may find their names among the authors in the following bibliography.

Ukrain Therapy - Protocols - Ambulent

Protocol for ambulant use of UKRAIN:

Ukrain Therapy - Protocols - Hospital

Protocol fot hospital use of UKRAIN:

Ukrain Therapy - Ukrainian Anti Cancer Institute - http://www.ukrin.com/en

Ukrain - Cancer Therapy: - Ukrain Therapy Completely Inhibited 57 out of 60 Different Human Cancer Cell Lines

Summary: A type of chemotherapy derived from a combination of two known cytotoxic drugs that are of little use individually, as the doses required for effective anticancer action are too high to be tolerated. However the combination is effective at far lower doses, with few side effects.

Description: Ukrain is a derivative of alkaloids that come from the greater celadine plant. Numerous scientific tests have shown that the preparations can destroy cancer cells through a process called apoptosis (programmed cell death) without harming healthy cells. Ukrain inhibits the formation of new blood vessels that supply the tumor with nutrients and also through which single tumor cells can migrate to other areas of the body. This leads to a starvation of the tumor and inhibits the formation of metastases. During the use, Ukrain activates a whole series of highly effective immune system mechanisms in the patient so that the bodys own resources start to combat the tumor.The drug is easy to use and is administered intravenously once a day for 10 days with very little in the way of side effects.

History: Ukrain was first developed in 1978 by Dr. Wassyl J. Nowicky, director of the Ukrain Anti-Cancer Institute of Vienna, who named this therapy after his native country (without the e).

Ukrain has been tested at the National Cancer Institute against 60 different human cancer cell lines and was found to completely inhibit the growth of cancer in 57 of them.

These included leukemia, melanoma, cancers of the lung, colon, brain, ovary, breast and kidney.Investigation of Ukrain Therapy is being continued in Austria, where it is produced, Canada, Germany, France, The Netherlands,Thailand, Swaziland and Switzerland. Only a few alternative practioners offer this therapy in the United States. 

Ukrain (NSC-631570) was first developed in 1978 by Dr. Wassyl J. Nowicky, director of the Ukrain Anti-Cancer Institute of Vienna, Austria and unveiled at the 13th International Congress of Chemotherapy in Vienna in August 1983.

Ukrain  is a semi-synthetic compound derived from the common weed, greater celandine (Chelidonium majus L.). This plant contains a range of alkaloids, most notably chelidonine, also known as benzophenanthridine alkaloid.

Ukrain is patented in both Europe and the U.S. and has been the subject of many scientific papers. There are clinical centers in Europe which are proposing it to cancer patients.

Ukrain is classified as a semisynthetic "reaction product" or "conjugate" created by Chelidonium majus L. and one of the oldest cytotoxic drugs, thiotepa.

Greater Celandine is a poppy-like plant, filled with a bright and acrid orange-colored juice. It has long been stated in the folk literature to have disease-fighting effects. According to a classic 1931 herbal, "greater celandine is a very popular medicine in Russia, where it is said to have proved effective in some cases of cancer".

Greater Celandine contains alkaloids, such as chelidonine, which have anticancer potential. By analogy, we know that the common periwinkle contains alkaloids that yield two standard anticancer agents, Vinblastine and Vincristine. Also, the plant astragalus yields an alkaloid called swainsonine, which has been shown at Howard University to have anticancer activity. Such alkaloids taken by themselves can be irritating or even toxic. So too is the drug thiotepa.

What makes Ukrain so unique is that this forced marriage of herb and drug yields a compound that is almost totally lacking in toxicity to normal cells. Yet it seems to have a strong affinity for killing cancer cells. In hamsters and rats, for example, no clinical signs of toxicity or damage to embryos could be found. The only toxicity was a slight decrease in the average hamster litter size. Nor does Ukrain induce anaphylactic shock in mice or guinea pigs. In addition, for three years healthy human volunteers in Poland, Austria, and Germany received repeated courses of the new drug. There was some local pain, and a few reported cases of drowsiness, as well as increased thirst and urge to urinate. But there were no other significant changes.

A leaflet distributed to patients at the Bristol Cancer Help Centre, United Kingdom, describes Ukrain as " the only known product, which at present does not also destroy healthy cells, and which reduces tumors and boosts the immune system..." (Bristol Cancer Help Centre 'handout' dated 05/03/2004 2004.).

Research on Ukrain started about 20 years ago. Meanwhile, numerous in-vitro studies, animal experiments , case reports, and case series have emerged.

Numerous pre-clinical and clinical investigations seem to suggest that Ukrain is pharmacologically active and clinically effective. Collectively, these data suggest that Ukrain has anticancer activity in a wide range of cell lines, which could be of clinical value. Whether or not this translates into clinical effectiveness and whether or not Ukrain does indeed cure some type of cancer or improves their prognosis can best be decided on the basis of randomised clinical trials (RCTs).

Relevant randomised clinical trials have been analysed by statistics researchers. However, the methodological quality of most studies was poor. In addition, the interpretation of several trials was impeded by other problems. The data from randomised clinical trials suggest Ukrain to have potential as an anticancer drug. However, numerous caveats prevent a positive conclusion, and independent rigorous studies are urgently needed.

Ukrain has been tested at the National Cancer Institute against 60 different human cancer cell lines and was found to completely inhibit the growth of cancer in 57 of them.

Ukrain Therapy - Hepatitis C

EFFICACY AND SAFETY OF THE DRUG UKRAIN IN CHRONIC HEPATITIS C PATIENTS

SOLOGUB T.V.1, VOLTCHEK I.V.2, KIVISEPP N.A.1, GRIGORYEVA T.1

1) Department of Infectious Diseases, St. Petersburg State Medical Academy, St. Petersburg, Russia.
2) Terra Medica Ltd., St. Petersburg, Russia.

Address for correspondence: Oleh Zahriychuk, Ukranian Anti-Cancer Institute, Margaretenstr. 7,1040 Vienna, Austria.

Summary: A total of 38 children, drawn from areas contaminated after the Chernobyl accident and suffering from recurrent bronchopulmonary pathology were included in the study To ascertain the effects of Ukrain, an anticancer and immunomodulating drug, it was administrated intravenously at a dose of 5 mg twice a week, up to a total dose of 35 mg.

The control group included 10 children with the same pathology who received stan­dard anti-inflammatory therapy Compared with the control group, the group treated with Ukrain showed marked anti-inflammatory activity: rapid decrease in white blood cell count and blood sedimentation rate.

The strong immunomodulatory effect of Ukrain was indicated through the improvement in specific humoral and cellular immunity: increases in the immunoglobulin G (IgG) level, the phagocytic activity of neutrophils, the number of total lymphocytes, T-lymphocytes and T-helpers, and the T-helpersIsuppressors ratio, in view of the positive results of this pilot study and the great importance of preventive and clinical investigation of this problem given the widespread distribution of nuclear power plants and of nuclear military equipment, further studies devoted to the impact of Ukrain on children with immune disorders from contaminated areas would be interesting and could lead to positive results.

Ukrain Therapy - Ukrainian Anti Cancer Institute - http://www.ukrin.com/en

Ukrain Therapy - Results - International Medical Research

Ukrain Therapy - Obstructive Tactics and their Consequences

Corruption is a destructive factor in society and unofficially bypasses the law. Our silence reinforces corruption and we are therefore all responsible for the consequences.

The sad story of Stefan Dan is known to many people from the book Buch „Krebsmittel Ukrain - Kriminalgeschichte einer Verhinderung“ von Dr. Eleonore Thun-Hohenstein (Molden Verlag, Vienna 2004), many press reports, (Link 1, Link 2, Link 3) from television ("Die Redaktion spezial", RTL2; "Mona Lisa", ZDF, 10 October 2004, 18:00,http://www.presseportal.de/meldung/604528) as well as from the specialist literature. (Link)

In 1993 the Arzneimittelbeirat (Pharmaceutical Advisory Board) at the Austrian Ministry of Health advised the use of Ukrain in accordance with § 42. (Link) In April 1995 Stefan's parents came to us with their sick child and a doctor's prescription ... (read more)

Ukrain Therapy vs Malignant Cells: Differentiated Effect of the Drug Ukrain on Normal and Malignant Cells: A Review

At the 89th annual meeting of the American Association for Cancer Research in New Orleans, March 28 – April 1, 1998 A. Panzer and J.C. Seegers (University of Pretoria, South Africa) presented their pioneering work on the selective effect of Ukrain on various cancer cell lines. Moreover, it has been first time as the fine mechanism of action of Ukrain had been described.

Ukrain Therapy - What is Ukrain Therapy? - Mechanisms of Action

Ukrain is a special extract from greater celandine using for the treatment of cancer.

Ukrain is the first and only anticancer drug accumulating during minutes after administration in cancer cells. Because it triggers apoptosis in cancer cells this drug is only toxic against cancer cells while, in contrast to chemotherapy, at therapeutic dose it leaves healthy cells undamaged. In 2004 and 2006 Dr. Wassil Nowicky, author of drug was nominated for the Nobel Prize for Chemistry.